|

NUMI Stock Deep Dive [ Will Numinus Wellness be a Leader in The Shroom BOOM?] 🤔

What’s up psychedelic investors! Today we’re finally going to cover the long anticipated NUMIStock. Numinus Wellness is a psychedelic Medicines company using a variety of compounds like psilocybin, MDMA and ketamine to treat for addiction, PTSD, depression and more. You can find the NUMI Stock on the TSX Venture exchange under the ticker symbol NUMI. NUMI stock is currently trading around 1$ Canadian, with a market cap of around $200 million. If you don’t want to purchase NUMI individually, Numinus can also be partially owned through an ETF like Horizons Psychedelic Stock Index or the upcoming Advisor Shares Plant Medicine ETF.

In this video we will cover the problems Numinus is trying to solve, their flagship programs, their financials, and finally the risks for the company. Numinus Wellness is one of the first psychedelic stocks we covered on this channel and the company has advanced quite nicely in the past few months, making it an interesting pick for the shroom boom!

Time Stamps
0:00 – Intro
1:20 – What Problem is Numinus trying to solve?
3:22 – NuMi Ketamine Treatments for Depression
4:50 – MDMA to treat PTSD
6:24 – Numinus Wellness Treating Addiction with Psilocybin
7:48 – Special Access Trials for MDMA and Psilocybin
9:02 – Psilocybin Extraction from Magic Mushrooms
9:39 – Financials and Cash on Hand
11:29 – Risks

https://www.newswire.ca/news-releases/numinus-wellness-closes-q1-2021-with-strong-cash-position-and-industry-firsts-867457159.html?fbclid=IwAR3gKruRdmOGIBZeRmS_xU-R_0J4WehW5TodKLx7SWK19DdpEeoZhM8O-2c#:~:text=Achievedcashbalanceof4915209,(1928737)forQ12021

So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

If you want to collaborate, send us an email!
thepsychedelicinvestor@gmail.com

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel
​…
​

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#NuminusWellness #NUMIStock #MindMed

Similar Posts

  • Interview With Dr. Joseph Tucker

    MagicMed Industries’ CEO, Dr. Joseph Tucker, talks about their psychedelic library, the company’s plans to go public and what the future of psychedelic research looks like.

  • A Deep Dive Into MindMed’s Microdosing Program: Project Flow | Plus a NEW LSD Microdosing Study

    In today’s episode, we look at MindMed’s (Nasdaq: MNMD, NEO: MMED) Project Flow, which is their LSD microdosing division. At present, MindMed’s microdosing program is split into 2 projects: base testing of LSD microdoses in healthy individuals, and using LSD microdoses to treat adult ADHD.

    We will explore the progress made on both fronts, and where the program will expand to in the future, such as psilocybin (magic mushrooms) microdosing.
    Ultimately, MindMed wants to answer questions such as:

    Can microdosing psychedelics treat ADHD?
    Can microdosing LSD improve your concentration?
    Can microdosing decrease your anxiety?
    Does microdosing increase creativity?
    Does microdosing improve your mood?

    Recently MindMed announced they are ready to begin recruiting for a study testing the variations in effect when taking LSD microdoses in the morning, compared to at night. The study will also try to answer the last four above questions. We discuss this study extensively.

    Links:
    MindMed Project Flow: https://mindmed.co/psychedelic-inspired/#scroll_section-2
    MindMed New study: https://psilocybinalpha.com/news/mindmed-launches-study-of-low-dose-lsd-effects-on-sleep-and-cognitive-measures

    Imperial College of London study: https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds

    Project Albert Quote: https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/

    Kim Kuypers Study: https://www.nature.com/articles/s41598-021-01811-4

    MindMed Investor’s Deck: https://mindmed.co/wp-content/uploads/2021/11/MindMed-Presentation-11.17-compressed.pdf

    LSD for ADHD: https://mindmed.co/news/press-release/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator/
    https://mindmed.co/news/press-release/mindmeds-microdosing-division-further-expands-phase-2-clinical-trial-of-microdosing-lsdfor-adult-adhd/

    Previous MindMed LSD study: https://mindmed.co/news/press-release/mindmed-announces-the-completion-of-phase-1-study-measuring-dosing-effects-of-lsd/

    Enjoy the episode!

    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy
    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Mindmed #MNMDstock #Microdosing

  • Interview with Joseph Mays, IRI Program Director at Chacruna

    In our conversation with Joseph, we chat a bit about some critical topics such as how psychedelics can allow us to understand the Indigenous philosophy of interrelatedness between one another and our ecosystems, the importance of considering sacred reciprocity to Indigenous peoples and their land, and how Chacruna’s Indigenous Reciprocity Initiative is making it simple for companies to give back to the societies who have cultivated psychedelic medicine.